PharmaLundensis AB (PHAL.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.317 (+0.00%) as of
Key statistics
- Market cap
- 20.38M
- EPS (TTM)
- -0.1100
- 52-week range
- 0.0414 – 1.2200
- Beta
- -0.37
- Profit margin
- 0.00%
- Volume
- 1.75M
About PharmaLundensis AB
PharmaLundensis AB engages in the development of drugs that bind and excrete heavy metals in Sweden. It develops Phal-501 for the treatment of lung diseases COPD and chronic bronchitis. The company was founded in 2006 and is based in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lund, Sweden
- Employees
- 2
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.